Our Deputy Director, Dr. Elissa Malkin, was a part of the Pfizer's newest study on its respiratory syncytial virus (RSV) vaccine, Abrysvo, which has shown to have a strong immune response in adults 18+.
Pfizer's RSV vaccine, Abrysvo, has shown a strong immune response and well-tolerated safety profile in new study.
Latest News
The CDC has released a new report on the health and economic benefits of routine childhood immunizations since the creation of the Vaccines for Children (VFC) program in 1994.
It's National Immunization Awareness Month! Getting vaccinated on the recommended schedule is an important part of protecting against many diseases. Please check with your trusted provider to see what vaccines are recommended for you!
The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were…